• Nicotinamide Riboside Chloride in iPSC-RGC Research

  2026-09-08

  Nicotinamide Riboside Chloride (NIAGEN) adds a controllable NAD+ metabolism variable to chemically defined retinal ganglion cell workflows. This guide separates evidence from the reference differentiation method and provides practical dosing, controls, and troubleshooting for metabolic dysfunction research and neurodegenerative disease models.

• AG-221 (Enasidenib): From 2-HG to Assay Design

  2026-09-07

  AG-221 (Enasidenib) is more than an IDH2 inhibitor: it is a tool for connecting 2-hydroxyglutarate reduction with epigenetic recovery, metabolic state, and leukemia cell differentiation. This article explains how recent CD44 findings can sharpen assay design in acute myeloid leukemia research.

• From Vaccine Breadth to Better Antibody Readouts

  2026-09-07

  Broad-spectrum vaccine development depends on more than demonstrating neutralization in animal models. This thought-leadership article explains how mechanistic assay design, species-aware detection, and the HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody can help translational teams convert human IgG measurements into reproducible evidence without confusing binding signals with functional protection.

• GKT137831: Dual Nox1/Nox4 Redox Workflows

  2026-09-05

  GKT137831 is a practical dual NADPH oxidase Nox1/Nox4 inhibitor for connecting ROS biology with vascular, fibrotic, metabolic, and membrane-damage assays. This guide provides concentration planning, ferroptosis-oriented readouts, workflow controls, and troubleshooting strategies for reproducible research use.

• AG-221 (Enasidenib): Assay Logic for IDH2 AML

  2026-09-04

  AG-221 (Enasidenib) enables a mechanism-led approach to IDH2-mutant AML research. This article shows how to connect 2-hydroxyglutarate reduction with differentiation, metabolic-state measurements, and CD44-dependent vulnerability rather than relying on viability alone.

• Chlorambucil: Separating Growth Arrest from Cell Death

  2026-09-04

  Chlorambucil is a nitrogen mustard alkylating agent whose DNA damage can produce both cytostasis and cell death. This guide applies a dissertation-derived framework to improve assay interpretation, distinguish relative from fractional viability, and design more informative cancer-cell experiments.

• How Inhibitors Accelerate p38α Dephosphorylation

  2026-09-03

  The reference preprint shows that some kinase inhibitors can do more than block p38α catalysis: they can also reshape its activation loop to make the regulatory phosphothreonine a better substrate for WIP1 phosphatase. This dual-action concept offers a biochemical framework for designing more durable and potentially more selective kinase inhibition, while requiring validation beyond the recombinant system.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-03

  Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability and show that it promotes prostate cancer bone metastasis through TRIM32-dependent control of calcium entry. The study connects a protein-interaction mechanism with metastatic phenotypes, providing a framework for investigating the STIM1–Ca2+ axis in prostate cancer research while highlighting the need for further therapeutic validation.

• Canagliflozin Workflows for Renal Research

  2026-09-02

  Build renal and metabolic assays around Canagliflozin’s selective SGLT2 activity, then extend glucose measurements with mitochondrial structure, respiration, and albuminuria endpoints. This practical workflow emphasizes solvent control, sex-aware analysis, and model-specific interpretation for more informative diabetes and kidney studies.

• Diphenyleneiodonium chloride in Cell Assays

  2026-09-02

  Diphenyleneiodonium chloride (DPI), SKU B6326, can help researchers separate redox-enzyme effects from assay artifacts in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers mechanism, solvent compatibility, protocol design, interpretation, and practical vendor selection.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-01

  The reference study identifies CD44 as a metabolic dependency created by IDH mutation in leukemia. Its results connect CD44-driven glucose rerouting to NADPH supply and R-2HG production, supporting combined targeting of mutant IDH and CD44 as a strategy for acute myeloid leukemia research.

• Fenipentol: From Chuanxiong Signal to Translation

  2026-09-01

  Fenipentol (1-Phenyl-1-pentanol) offers translational researchers a defined small-molecule entry point into secretory physiology, ESR1-linked signaling, and the source-resolved pharmacology of Ligusticum chuanxiong. This article connects mechanistic hypotheses with validation strategy, formulation discipline, toxicology context, and a differentiated path beyond conventional product-page descriptions.

• Angiotensin I/II (1-5) Protocol Guide

  2026-08-31

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research, including blood pressure and aldosterone-related assays. It is intended for validated cardiovascular or renal models and should not be treated as interchangeable with full-length angiotensin peptides or applied to unrelated signaling workflows without independent validation.

• 5-(N,N-dimethyl)-Amiloride in Endothelial Models

  2026-08-31

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride as a pharmacological probe to connect Na+/H+ exchanger activity with intracellular pH regulation, endothelial barrier failure, and cardiac injury phenotypes. This workflow combines real-time ion measurements with permeability, signaling, and moesin assays while clearly separating established evidence from testable sepsis-model hypotheses.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-30

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phospho-threonine to WIP1, accelerating dephosphorylation. Its structural and biochemical results introduce a conformation-focused strategy for improving kinase-inhibitor potency and specificity while clarifying how kinase state may influence phosphatase recognition.

8571 records 1/572 page Next 12345 下5页 Last page